Quantcast

Latest Psoriatic arthritis Stories

2014-04-30 12:30:11

Expert Opinion Indicates That Humira and Cimzia Have the Best Clinical Profiles of Key Marketed Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 30, 2014 /PRNewswire/ --Decision Resources Group finds that, when asked to select the top three most persuasive end points when prescribing a new drug for psoriatic arthritis (PsA), the highest percentages of surveyed United States and European rheumatologists selected the American College of Rheumatology (ACR)...

2014-04-28 08:28:32

Celebrate the Spirit of Arthritis Awareness Month by Participating in the Walk to Cure Arthritis in Your Community LOS ANGELES, April 28, 2014 /PRNewswire-USNewswire/ -- Help find a cure by participating in and fundraising for the 2014 Walk to Cure Arthritis. Formerly known as Arthritis Walk, Walk to Cure Arthritis is the Arthritis Foundation's signature, national fundraising event to prevent, control and cure the nation's leading cause of disability. Funds raised through local...

2014-04-24 12:29:49

First U.S. registry to collect both physician and patient data on psoriatic arthritis PORTLAND, Ore., April 24, 2014 /PRNewswire-USNewswire/ -- To improve treatment decisions and patient outcomes for psoriatic arthritis (PsA)--a chronic inflammatory arthritis that affects the joints and tendons--the National Psoriasis Foundation (NPF) and Corrona, LLC (Corrona) are collaborating to give NPF-affiliated researchers access to Corrona's psoriatic arthritis registry, which is the largest...

2014-04-20 23:01:04

ReportsnReports.com offers Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research report in its store. Dallas, TX (PRWEB) April 20, 2014 Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research report says that over the last decades, therapeutic options for Plaque...

2014-04-16 23:14:45

In May, over three dozen nonprofits around the world, along with thousands of patients, supporters, practitioners, and researchers, will unite under one ‘virtual roof’ to participate in the largest educational & awareness event in Autoimmune Arthritis history. Los Angeles, CA (PRWEB) April 16, 2014 At 6am ET/USA on May 19th, 2014, the online Virtual Convention doors to World Autoimmune Arthritis Day (WAAD14) will open and 1,000’s of attendees from dozens of countries around the...

2014-04-14 20:22:24

FORT WORTH, Texas, April 14, 2014 /PRNewswire/ -- ReCept announces that it is among a select group of specialty pharmacies selected by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule which works by blocking the enzyme phosphodiesterase 4 to reduce swelling in joints and improve physical function in a form of arthritis that afflicts psoriasis sufferers. Approved by the FDA on March 21, 2014 and...

2014-04-10 11:29:47

Rheumatoid arthritis patients are likelier than the average person to develop chronic kidney disease, and more severe inflammation in the first year of rheumatoid arthritis, corticosteroid use, high blood pressure and obesity are among the risk factors, new Mayo Clinic research shows.  Physicians should test rheumatoid arthritis patients periodically for signs of kidney problems, and patients should work to keep blood pressure under control, avoid a high-salt diet, and eliminate or scale...

2014-04-04 12:27:14

FLINT, Mich., April 4, 2014 /PRNewswire-iReach/ -- Diplomat has announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). Otezla® was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. Diplomat...

2014-03-27 12:29:39

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5sfksl/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Psoriasis - Plaque Psoriasis & Psoriatic Arthritis - Novel Oral Drugs And Biologics To Change Future Treatment Paradigm" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and...

2014-03-25 08:28:54

PETACH TIKVA, Israel, March 25, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 9(th) International Congress of Autoimmunity. The conference will be held on March 26-30, 2014 at Nice Acropolis Convention Center in Nice, France. On Friday March 28(th), 16:30, Can-Fite...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related